Biogen-Sage setback, biotech IPOs and Sanofi’s digital revamp: a BioCentury podcast
What FDA complete response in MDD means for Zurzuvae. Plus: IPO prospects for crossover-backed biotechs, and a pharma’s digital revolution
By Jeff Cranmer, Executive Editor
August 7, 2023 11:59 PM UTC
A complete response letter from FDA in major depressive disorder could severely dent the commercial prospects for Zurzuvae zuranolone even as the drug gained approval for postpartum depression. On the latest BioCentury This Week podcast, BioCentury’s editors assess what the agency’s decision, which included a request for at least one additional study, means for Biogen Inc. (NASDAQ:BIIB) and its partner Sage Therapeutics Inc. (NASDAQ:SAGE).
BioCentury’s editors also discuss the thawing market for biotech IPOs, zeroing in on the dozens of companies that raised crossover cash before markets turned sour, as well as the digital transformation under way at Sanofi (Euronext:SAN; NASDAQ:SNY), which aims to use AI and data science to drive everything from candidate discovery to clinical trial planning, manufacturing optimization and supply chain management.
BioCentury This Week is sponsored by the BioCentury-BayHelix East-West BioPharma Summit, which takes place in Cambridge, Mass., Oct 2-4. For information on how to sponsor The BioCentury Show and the BioCentury This Week podcast, please contact Sarah Shoaff at sarah.shoaff@biocentury.com.
